United Therapeutics (NASDAQ:UTHR) CEO Sells $5,481,215.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $576.97, for a total value of $5,481,215.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,374,785.61. The trade was a 19.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

United Therapeutics Price Performance

NASDAQ UTHR opened at $569.18 on Friday. The business has a 50 day simple moving average of $550.17 and a 200 day simple moving average of $501.37. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a market capitalization of $24.05 billion, a P/E ratio of 21.01, a P/E/G ratio of 1.70 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period in the prior year, the business earned $6.63 EPS. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities analysts expect that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on UTHR shares. Royal Bank Of Canada decreased their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday. TD Cowen raised their target price on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Finally, Oppenheimer raised their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors focused on product/catalyst upside — market reaction was supported by management highlighting positive Tyvaso data in IPF and continued optimism around ralinepag’s blockbuster potential, which many say could drive significant future growth. UTHR Q1 Earnings Miss — Shares Jump on Strong Outlook
• Positive Sentiment: Partnership expansion with MannKind around DPI technology may improve delivery/manufacturing optionality and was reported to boost MannKind’s stock — a potential operational positive for United Therapeutics’ inhaled product ambitions. MannKind Stock Surges on Partnership
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly from $707 to $701 but retained an “outperform” rating, leaving a sizable implied upside from current levels; this is broadly supportive but not catalytic. RBC Lowers PT to $701
• Negative Sentiment: Q1 financials missed consensus: EPS of $5.82 vs. estimates near $7.00 and revenue $781.5M vs. ~$797M — revenue declined ~2% YoY. The miss can pressure short-term sentiment despite healthy margins. Q1 2026 Financial Results
• Negative Sentiment: Significant insider selling: CEO Martine Rothblatt sold 9,500 shares (~19% reduction in her disclosed holding) and EVP Paul Mahon sold 8,300 shares (~15.5% reduction). Large, contemporaneous insider reductions can weigh on sentiment, especially after an earnings miss. Rothblatt SEC Filing Mahon SEC Filing

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. Torren Management LLC bought a new position in United Therapeutics in the fourth quarter worth approximately $26,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC boosted its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in United Therapeutics in the fourth quarter worth approximately $31,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.